ustwo brings AI governance to the boardroom with appointment of Google DeepMind executive Simon Bouton July 29, 2026 ustwo, the global employee-owned B Corp digital product studio, today announced the appointment of Simon Bouton, Chief Experience Officer at Google DeepMind, as its first AI Non-Executive Director. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260728923967/en/ Bouton joins the board to provide independent oversight of ustwo’s AI strategy, reflecting the studio’s conviction [...]
Logitech Announces Q1 Fiscal Year 2027 Results July 28, 2026 Strong First Quarter Marks Tenth Consecutive Quarter of Growth
Options Strengthens North America Presence with New York Office Expansion In the Heart of Wall Street July 28, 2026 Options Technology (Options), the leading provider of IT infrastructure to global financial institution managed services, today announced the expansion of its New York office. This expansion comes after increased client growth and surging demand across North America for the firm’s trading infrastructure and market data solutions. The 34,000 square foot office, located in the heart [...]
Sweeping job cuts at GSK to fund £400m Cambridge campus July 28, 2026 GSK is poised to slash its back office headcount to help fund a £400m mega-campus in Cambridge, in a move it hopes will bolster its drugs pipeline anFd stave off a looming patent cliff-edge. In his first major update as chief executive, Luke Miels unveiled plans to find £1.9bn of savings over the next three [...]
Ten Finalists Announced for the Reply AI Film Festival, the International Competition Bringing Together Cinema and Artificial Intelligence July 28, 2026 The jury, chaired by Gabriele Salvatores, will announce the winners in Venice on Sunday, 6 September.
Trust, stability, resilience and innovation – the cornerstones of 25+ years of cybersecurity leadership July 27, 2026 The digital transformation drive has completely changed organisations’ operational and technological architectures. SaaS, cloud and now AI have brought with them a wealth of fiscal and productivity benefits, however, they have also led to increased organisational complexity and, from a cybersecurity perspective, a considerably expanded attack surface. AI has equipped malicious actors with tools to [...]
‘Extremely dangerous’: AI warfare much bigger threat than LLM model advances, experts warn July 25, 2026 The growing use of AI in warfare poses a much bigger threat to the future of the UK than the latest advances in frontier AI models, experts have told City AM. Nicholas Fairfax and Max Rangeley, co-editors of The Artificial Intelligence Revolution, said the ability of small actors to use AI to develop immensely powerful [...]
Almirall H1 2026 Results July 24, 2026 Almirall delivers solid H1 2026 results growing Net Sales by 7.5% and EBITDA by 23.7%, driven by its strong European Dermatology business – reiterating guidance aligned with long-term growth trajectory Net Sales increased by 7.5% YoY to €602.7 MM, while EBITDA grew by 23.7% to €150.7 MM, reflecting strong commercial and operational execution. The European Dermatology business continues to drive growth, increasing 18.1% YoY to €341.9 MM, supported by strong performance of its key growth drivers and favourable underlying market growth. Continued solid performance of the biologics portfolio, with Ilumetri® delivering 10.5% increase to €125.2 MM and Ebglyss® growing 88.2% to €84.5 MM in Net Sales, supported by sustained growth in recent launch markets. The broader dermatology portfolio delivers positive performance, including Wynzora® (19.3%, total of €20.4 MM) and Klisyri® (13.9%, total of €15.6 MM). Almirall advances its innovation strategy through progress across its R&D pipeline, including four ongoing PoC/Phase II studies and two additional PoC studies planned to be initiated by end of 2026, targeting five dermatological diseases. The first readouts are expected towards the end of 2026. Almirall signs a strategic research collaboration and licensing agreement with Certest Biotec to discover and develop novel treatments for rare dermatologic diseases and recurrent cutaneous conditions. Reiterated guidance for the full year 2026: 9-12% growth and € 270MM to € 290MM EBITDA.
AI spending overshadows Alphabet and Tesla earnings July 23, 2026 Wall Street’s biggest tech companies delivered another round of strong earnings on Wednesday, but the primary focus for investors is the growing cost of the artificial intelligence race. Alphabet and Tesla beat revenue expectations, yet their shares fell in after-hours trading after both companies signalled another year of heavy spending on AI infrastructure. Google-owner Alphabet [...]
City law firms considering corporate-style models amid capital crunch July 23, 2026 Artificial intelligence investment may force top City firms to abandon the traditional limited liability partnership (LLP) mindset and behave like capital‑hungry corporates, a top legal finance firm has predicted. Speaking to City AM, Burford Capital’s chief operating officer, Travis Lenkner, and vice president, Patrick Savage, said City law firms that would never traditionally sell a controlling [...]